Detection of exogenous insulin in blood and urine in type I diabetics and non diabetics.
Detection of exogenous insulin (in blood and urine) as a doping agent in 6 type I diabetics and 6 non diabetics, both male and female, aged 18 to 45. An open label cross over study.
Concord Repatriation General Hospital
12 participants
Oct 1, 2007
Interventional
Conditions
Summary
Sports anti doping study. The aim of the study is to obtain specimens of urine and blood from voluneers who have been given an injection of insulin. These samples will then be used to develop tests which will help detect the presence of insulin in the blood and urine of elite athletes who have used insulin illicitly to enhance their performance.
Eligibility
Inclusion Criteria8
- Type I diabetics:
- on insulin therapy
- Male or female
- Aged 18 to 45.
- Non diabetics:
- Healthy
- Male or female
- Aged 18 to 45
Exclusion Criteria6
- In non diabetic group:
- Coronary artery disease
- epilepsy
- diabetes
- elite athletes
- pregnancy
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Type I diabetic participants take their usual insulin dose and provide blood and urine samples at baseline and for up to 24 hours. Non diabetic participants are administered intravenous (IV) Actrapid insulin 0.05iu/kg at visit 1, 70g oral glucose at visit 2 and placebo at visit 3. Blood and urine samples are collected at each visit at baseline then for up to 24 hours. There is a 5 day washout period between visit 1 (insulin administration) and visit 2 (glucose administration). There is no specified washout period between visit 2 and visit 3 (placebo administration).
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000237381